Ordering
Available Variants5 mg
CHA.39976-5mg
Price
€208.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.39976-5mg | €208.80 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C18H23NO3S |
|---|---|
| CAS Number | 74772-77-3 |
| Molecular Weight | 333.45 |
| NACRES | NA.77 |
| PubChem Substance ID | 24892661 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD00865499 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 10 - Combustible liquids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, multi-purpose combination respirator cartridge (US) |
Technical Overview & Applications Use-case context
Ciglitizone, with a chemical abstracts service number of 74772-77-3, is a thiazolidinedione derivative that has been investigated for its potential therapeutic applications. It is known to act as a selective agonist of peroxisome proliferator-activated receptor gamma, which plays a crucial role in regulating glucose and lipid metabolism. The activation of this receptor by ciglitizone has been shown to improve insulin sensitivity and glucose uptake in various tissues, making it a potential candidate for the treatment of type 2 diabetes. Additionally, ciglitizone has been found to exhibit anti-inflammatory properties, which may contribute to its therapeutic effects. Further research is needed to fully elucidate the pharmacological profile of ciglitizone and to explore its potential as a therapeutic agent for the management of metabolic disorders. Its mechanism of action and potential benefits warrant continued investigation in the scientific community.
